Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b.
about
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsOxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.Fluorescence single particle tracking for the characterization of submicron protein aggregates in biological fluids and complex formulations.Classification and characterization of therapeutic antibody aggregates.Aggregation of a multidomain protein: a coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stressSafety and immunotoxicity assessment of immunomodulatory monoclonal antibodiesBioactivity determination of native and variant forms of therapeutic interferons.Silylated precision particles for controlled release of proteins.Chemical modifications in aggregates of recombinant human insulin induced by metal-catalyzed oxidation: covalent cross-linking via michael addition to tyrosine oxidation products.Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responsesComparative study of idursulfase beta and idursulfase in vitro and in vivo.Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice.Extrinsic fluorescent dyes as tools for protein characterizationIdentification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon Beta-1a: potential implications for protein aggregation and immunogenicityOverview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics.Immunogenicity of therapeutic proteins: the use of animal models.Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.Oxidation of therapeutic proteins and peptides: structural and biological consequences.Study on the effect of solution conditions on heat induced-aggregation of human alpha interferon.Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.UV photodegradation of murine growth hormone: chemical analysis and immunogenicity consequences.Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting.Sensitive spectroscopic detection of large and denatured protein aggregates in solution by use of the fluorescent dye Nile red.Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity.The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling.Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality.Development of antibody arrays for monoclonal antibody Higher Order Structure analysis.Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics.Antibody response against Betaferon® in immune tolerant mice: involvement of marginal zone B-cells and CD4+ T-cells and apparent lack of immunological memory.Development of a transgenic mouse model with immune tolerance for human coagulation factor VIIa.Factors affecting the physical stability (aggregation) of peptide therapeutics.Chemical and Biophysical Characteristics of Monoclonal Antibody Solutions Containing Aggregates Formed during Metal Catalyzed Oxidation.Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.Distinct Immunologic Properties of Soluble Versus Particulate Antigens.Improving Immunotherapy Through Glycodesign
P2860
Q26738810-8E7885E4-A4CB-44AF-8EB3-873C738C5727Q30402355-C7F41E63-C603-4266-8BB1-950B791CADDEQ30499391-D38154A0-47FA-453A-B6B7-C3CA71EA87A0Q30502491-D058ED09-35DF-4EB6-B321-CCCE5F31F5C8Q33834215-EB0EF48F-FD7A-46AB-A9BF-02F7C633A5D2Q33895804-A24884D3-AC62-469B-9B88-9CEA26A4121DQ34635157-24CE628E-6A5F-4A8A-8459-63BD62DC02A9Q35983600-E162BA5F-AE1A-41B4-B28E-6572F081227DQ36101274-C21920B1-53B6-4A60-A121-058269373839Q36126960-54E47749-100F-4879-8450-208D1CF708DAQ36188048-D0A82BBD-E240-4B78-BB7F-ECE7610D327FQ36411853-98FE936B-CE66-43FC-9EA9-EBC4C5CC6B7FQ36738230-43D71F65-D169-4E4F-9C41-77C009C678A1Q37078660-7D83C838-1D3A-43B2-8C1A-9015F40980F0Q37311030-D72B6DBC-3C02-4DC8-AD0C-9B6EE58ED9B0Q37899800-1669F12F-EB3C-46A3-8489-B92331FFB86CQ38048706-15AF23EB-7B9A-4369-9673-C2C6DDAE0A90Q38142887-6075A2DE-938C-4BDC-8915-EF0D084DDD87Q38627828-8D5A2E23-8701-4A31-A3D8-EBF85C5FA3C6Q38798188-97998B72-2463-4567-9AE5-3159FC7EA53CQ40997642-C71EF6CA-EA1A-4275-BDE6-2691B22A6FDCQ41353938-6B1FC0B5-0257-4347-9D15-DC4F7C447349Q41768509-9DB1DC3B-CE28-42CA-9877-79ABB03BBAA1Q41944133-8739DCBD-7012-4355-A4B0-77B759E393D3Q41953123-2612A5AB-0FFE-4DDA-962F-AF316B1DDEFEQ41963402-84D9C082-9491-4EA0-B7F2-3A425FEBB469Q42142843-FBD69B27-0DD3-4BC4-85DD-526E1357409FQ42578789-A491D1E9-60A3-4AFC-96C9-F7F647E38D5BQ44285833-B35A43F4-4BF4-471A-AC5E-6EB027FA3C8BQ44805804-814E1D8B-57FA-4FDF-BD8F-81CB12AC94C3Q45888396-BC18F990-96AC-4903-A553-953A13C22504Q46259884-7D66F40F-CC25-4F03-8F24-445BAD16B499Q46267230-76989DB2-1AFF-4599-B46C-4EFB61E79582Q50034109-664A28A3-C682-4E8C-B169-EDE0E6D2E402Q50146186-9924F4B5-AFD8-4D14-9112-14AF1F97ABE3Q52684751-F1339B7B-0D39-4B7A-92BA-6E0B9D040063Q55270638-FECD9689-A8AE-4124-9188-504B81E3E51BQ59132146-2554EDCE-41C9-4322-9194-25F2ED935C74
P2860
Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Structural characterization an ...... nant human interferon alpha2b.
@ast
Structural characterization an ...... nant human interferon alpha2b.
@en
type
label
Structural characterization an ...... nant human interferon alpha2b.
@ast
Structural characterization an ...... nant human interferon alpha2b.
@en
prefLabel
Structural characterization an ...... nant human interferon alpha2b.
@ast
Structural characterization an ...... nant human interferon alpha2b.
@en
P2093
P1476
Structural characterization an ...... nant human interferon alpha2b.
@en
P2093
Daan J A Crommelin
Huub Schellekens
J Mirjam A Damen
Liliana Aranha
Monique Slijper
Suzanne Hermeling
Wim Jiskoot
P2860
P304
P356
10.1007/S11095-005-8177-9
P577
2005-10-03T00:00:00Z